1. Show article details.

    Pfizer agreed to supply additional COVID-19 vaccines, says Japan's vaccine minister

    Reuters – 11:26 PM ET 04/17/2021

    Pfizer CEO Albert Bourla has agreed to Japanese Prime Minister Yoshihide Suga's request to supply additional doses of the COVID-19 vaccine, the vaccine minister of Japan said on Sunday. "They have agreed on the essentials of the matter," vaccine tzar Taro Kono said during a live interview on Fuji TV, adding that further details including the shipment schedule will be discussed.

  2. Show article details.

    Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan

    Reuters – 5:20 PM ET 04/17/2021

    Japanese Prime Minister Yoshihide Suga asked U.S. drugmaker Pfizer Inc (PFE) on Saturday to provide additional supplies of COVID-19 vaccine to Japan this year, Nikkei reported. Pfizer confirmed in an email that Pfizer CEO Albert Bourla met with Suga virtually to discuss vaccine supply on the last day of Suga's three-day visit to Washington.

  3. Show article details.

    U.S. administers 205.9 mln doses of COVID-19 vaccines

    Reuters – 2:30 PM ET 04/17/2021

    The United States has administered 205,871,913 doses of COVID-19 vaccines in the country as of Saturday morning and distributed 264,499,715 doses, the U.S. Centers for Disease Control and Prevention said on Saturday. Those figures are up from the 202,282,923 vaccine doses the CDC said had gone into arms by April 16 out of 258,502,815 doses delivered.

  4. Show article details.

    Japanese PM Suga asks Pfizer to send Japan more COVID-19 vaccines - Nikkei

    Reuters – 1:56 PM ET 04/17/2021

    Japanese Prime Minister Yoshihide Suga asked U.S. drugmaker Pfizer Inc (PFE) on Saturday to provide additional supplies of COVID-19 vaccine to Japan, Nikkei reported, citing Japanese officials. Suga made the request during a telephone call with Pfizer CEO Albert Bourla on the last day of a three-day visit to Washington, according to the report https://s.nikkei.com/3tFjb4E.

  5. Show article details.

    U.S. parents begin to ask: Should my child get a COVID-19 shot?

    Reuters – 12:47 PM ET 04/17/2021

    Tristen Sweeten, a 34-year-old nurse in Utah, hopes her three children will receive Moderna's COVID-19 vaccine through its pediatric clinical trial. Angie Ankoma, a 45-year-old Black mother of four who works in philanthropy in Rhode Island, believes trials must include diverse populations and participated in one for a COVID-19 vaccine herself.

  6. Show article details.

    Dubai expands vaccine eligibility in certain cases

    Reuters – 6:18 AM ET 04/17/2021

    The Dubai Health Authority said on Saturday it was allowing women who are breastfeeding and those planning on conceiving to take the Pfizer-BioNTech COVID-19 vaccine, according to the Dubai Media Office. In a Twitter post, the media office said this was in line with the latest international studies and guidelines on coronavirus vaccines.

  7. Show article details.

    Australia to continue review of COVID vaccinations - health minister

    Reuters – 1:01 AM ET 04/17/2021

    Australia will continue its review of coronavirus vaccines after a 48-year-old woman's death was likely linked to the inoculation, Health Minister Greg Hunt said on Saturday. On Friday, Australia reported its first fatality from blood clots in a recipient of AstraZeneca's COVID-19 shot.

  8. Show article details.

    Senators urge Biden to back temporary WTO waiver of IP rights to speed vaccine access

    Reuters – 3:48 PM ET 04/16/2021

    Bernie Sanders and nine other Democratic senators urged President Joe Biden on Friday to back a temporary patent waiver for COVID-19 vaccines that would allow countries to manufacture treatments locally and accelerate the global vaccination effort.

  9. Show article details.

    BRIEF-Canada says Pfizer has asked to expand usage of its COVID-19 vaccine 12-year-olds and up

    Reuters – 3:44 PM ET 04/16/2021

    Canada's Health ministry says Pfizer Inc (PFE) has submitted request: * TO EXPAND USE OF ITS COVID-19 VACCINE TO 12-15 YEAR-OLDS; CURRENTLY USED ONLY FOR 16 YEARS AND UP Further company coverage:

  10. Show article details.

    Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.

    DJ Business News – 3:22 PM ET 04/16/2021

    Moderna Inc. (MRNA) expects a shortfall in Covid-19 vaccine doses it will deliver to countries outside the U.S., including Canada and the U.K., citing issues with its European supply chain. The Cambridge, Mass., company said Friday the dose shortfall affects expected deliveries for the second quarter in a number of countries but didn't specify others beyond Canada and the U.K. The manufacturing problems won't affect U.S. supplies.

  11. Show article details.

    U.S. administers 202.3 mln doses of COVID-19 vaccines - CDC

    Reuters – 1:57 PM ET 04/16/2021

    The United States has administered 202,282,923 doses of COVID-19 vaccines in the country as of Friday morning and distributed 258,502,815 doses, the U.S. Centers for Disease Control and Prevention said on Friday. Those figures are up from the 198,317,040 vaccine doses the CDC said had gone into arms by April 15 out of 255,400,665 doses delivered.

  12. Show article details.

    BRIEF-U.S. CDC Says Delivered 258,502,815 Doses Of COVID-19 Vaccine As Of April 16

    Reuters – 1:36 PM ET 04/16/2021


  13. Show article details.

    Pregnant women in UK told to have Pfizer or Moderna vaccines

    Reuters – 12:51 PM ET 04/16/2021

    Pregnant women in Britain should get a COVID-19 vaccine made by Pfizer or Moderna (MRNA) because there is more real-world data to show they are safe, the British public body that advises on vaccinations said on Friday.

  14. Show article details.

    BRIEF-Canada PM Trudeau says Toronto is struggling to deal with third wave of COVID-19, federal gov't will do whatever it takes to help

    Reuters – 11:52 AM ET 04/16/2021


  15. Show article details.

    Biden administration to invest $1.7 billion to fight COVID-19 variants

    Reuters – 10:30 AM ET 04/16/2021

    The Biden administration on Friday said it will invest $1.7 billion to help states and the U.S. Centers for Disease Control and Prevention fight COVID-19 variants that are rapidly spreading across the United States.

  16. Show article details.

    Game changer: Chile hails Sinovac's 67% effectiveness in study

    Reuters – 10:07 AM ET 04/16/2021

    China's Sinovac COVID-19 vaccine was 67% effective in preventing symptomatic infection, data from a huge real-world study in Chile has shown, a potential boost for the jab which has come under scrutiny over its level of protection against the virus.

  17. Show article details.

    Madrid may shut down mass vaccination centres unless more shots arrive

    Reuters – 9:24 AM ET 04/16/2021

    A shortage of coronavirus shots may force the Madrid region to close down mass vaccination centres next week, the regional public health chief said on Friday, as infections in the Spanish capital outpace the national average.

  18. Show article details.

    Australia reports first blood clot death 'likely' linked to AstraZeneca vaccine

    Reuters – 8:48 AM ET 04/16/2021

    Australia on Friday reported its first fatality from blood clots in a recipient of AstraZeneca's COVID-19 shot, and its regulator said there was a likely link between the 48-year-old woman's death and the vaccine. Hers was the third instance of the rare blood clots appearing in people who have been administered the vaccine in Australia.

  19. Show article details.

    BRIEF-China Plans To Approve First Foreign COVID-19 Vaccine By July - WSJ

    Reuters – 8:11 AM ET 04/16/2021

    * CHINA PLANS TO APPROVE FIRST FOREIGN COVID-19 VACCINE BY JULY - WSJ Source: https://on.wsj.com/3tu4D84.

  20. Show article details.

    Johnson & Johnson asked rival COVID-19 vaccine makers to probe clotting risks - WSJ

    Reuters – 7:10 AM ET 04/16/2021

    Johnson & Johnson (JNJ) had reached out to rival COVID-19 vaccine makers to join in an effort to study the risks of blood clots, but Pfizer Inc (PFE) and Moderna (MRNA) declined, the Wall Street Journal reported on Friday. Only AstraZeneca (AZN), which had been buffeted by similar blood-clotting concerns for weeks, agreed, the report said, citing people familiar with the matter.


Today's and Upcoming Events

  • May

    PFE to announce Q1 earnings (Confirmed)

Past Events (last 90 days)

  • Feb

    PFE announced Q4 earnings.

  • Jan

    PFE ex-Dividend for $0.39 on 01/28/2021

    • Announce Date: 12/11/2020
    • Record Date: 01/29/2021
    • Pay Date: 03/05/2021
Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.